Skip to main content

Table 3 Uni- and multivariate analysis for overall survival in the derivation cohort

From: A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function

Variables

Univariate analysis

Regression coefficient (ß)

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

Sex

 Female

0.940

(0.662–1.335)

0.731

    

Age (year)

1.024

(1.012–1.037)

< 0.001

    

Etiology

 Non-Viral

ref

      

 Viral

0.616

(0.437–0.870)

0.006

    

Child-Pugh class

 A

ref

      

 B

1.591

(1.143–2.213)

0.006

    

ALBI grade

 1

ref

      

 2

2.231

(1.605–3.101)

<.0001

    

 3

6.602

(3.409–12.786)

<.0001

0.832

2.299

(1.694–3.119)

<.0001

HAP score

 A-C

ref

      

 D

3.937

(2.872–5.399)

<.0001

    

Modified HAP score

 A-C

ref

      

 D

4.689

(3.012–7.300)

<.0001

    

Tumor number

 ≤3

ref

      

 > 3

1.615

(1.155–2.259)

0.005

    

Tumor size (cm)

 < 3

ref

      

 3–4

1.775

(1.231–2.560)

0.002

    

 ≥5

3.359

(2.368–4.763)

<.0001

0.533

1.704

(1.424–2.038)

<.0001

Hemoglobin (g/dL)

0.851

(0.796–0.909)

<.0001

    

Log WBC

1.452

(0.988–2.132)

0.058

    

Log platelet

1.165

(0.875–1.551)

0.296

    

Log prothrombin time (INR)

9.847

(3.454–28.076)

<.0001

    

Log creatinine

1.907

(1.377–2.640)

<.0001

    

Sodium

0.937

(0.898–0.977)

0.002

    

Log AST

2.332

(1.833–2.966)

<.0001

    

Log ALT

1.231

(1.010–1.499)

0.039

    

Log Total bilirubin

1.191

(0.900–1.574)

0.221

    

Alpha-fetoprotein

 < 200

ref

      

 ≥200

1.774

(1.313–2.397)

<.0001

0.460

1.583

(1.164–2.154)

0.0034

NLR

1.91

(1.444–2.525)

<.0001

    

Tumor response

 CR + PR

ref

      

 SD + PD

2.292

(1.733–3.032)

<.0001

0.650

1.915

(1.431–2.563)

<.0001

  1. Abbreviations: HR hazards ratio, ref. reference, ALBI albumin-bilirubin grade, HAP score hepatoma arterial-embolization prognostic score, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, NLR neutrophil-lymphocyte ratio, CR complete response, PR partial response, SD stable disease, PD progressive disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us